cGMP analog for neuroprotection
Inherited Retinal Diseases (Retinitis Pigmentosa, Leber's Congenital Amaurosis, Stargardt's disease)
Key Facts
About Mireca Medicines
Mireca Medicines is a private, preclinical-stage biotechnology company based in Munich (with R&D in Tübingen), Germany, developing novel cGMP-analog therapeutics. Its lead program targets the inhibition of protein kinase G (PKG) to provide neuroprotection in a broad range of inherited retinal diseases, a strategy supported by positive preclinical data. The company is built on foundational science from a long-running European consortium and is led by a team with entrepreneurial and ophthalmology research expertise. Mireca's approach addresses a common disease mechanism across many genetic mutations, positioning it to potentially treat a significant orphan disease population.
View full company profile